Tatva Chintan Pharma Chem Ltd Financials
Company Logo

Tatva Chintan Pharma Chem Ltd Financial Statement

Tatva Chintan Pharma Chem Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue81.77
Operating Expense76.36
Net Profit-1.11
Net Profit Margin-1.36
Earning Per Share-0.47
EBIDTA5.58
Effective Tax Rate-5.36

Tatva Chintan Pharma Chem Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual378.68
Operating Expenses Annual311.81
Operating Profit Annual74.37
Interest Annual6.51
Depreciation25.15
Net Profit Annual29.35
Tax Annual12.92

Tatva Chintan Pharma Chem Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning21.19
Cash Flow from Operations102.78
Cash Flow from Investing-120.52
Cash Flow from Financing30.54
Cash Flow at the End33.99

Tatva Chintan Pharma Chem Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)19.68
PBIT Margin (%)12.92
PBT Margin (%)10.98
Net PROFIT Margin (%)7.75
Return On Networth / Equity (%)4.77
Return On Networth /Employed (%)6.90
Return On Assets (%)4.11
Total Debt / Equity (X)0.15
Asset Turnover Ratio (%)0.53

Tatva Chintan Pharma Chem Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual430.48
Total Current Assets Annual293.61
Non Current Assets Annual521.46
Total Shareholders Funds Annual725.88
Total Assets Annual815.07

Tatva Chintan Pharma Chem Ltd Earning Calls

EPS (INR)

Expected

0.00

Reported

-0.29

Surprise

0.00%

Jun 2024

EPS beaten by 0.00%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 5, 2024, Tatva Chintan Pharma Chem Ltd has a market capitalization of 2,525.29 Cr. Value Research classifies it as a Mid-Cap company.
Yes, Tatva Chintan Pharma Chem Ltd is debt-free with a debt-to-equity ratio of 0.02.
In FY 2023 , Tatva Chintan Pharma Chem Ltd recorded a total revenue of approximately 378.68 Cr marking a significant milestone in the company's financial performance.
Tatva Chintan Pharma Chem Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately -0.4% and -0.1% annually, respectively..
Tatva Chintan Pharma Chem Ltd's current PE ratio is 86.04.
Tatva Chintan Pharma Chem Ltd's ROCE averaged 10.7% from the FY ending March 2022 to 2024, with a median of 7.0%. It peaked at 18.4% in March 2022, reflecting strong capital efficiency over the period..
Tatva Chintan Pharma Chem Ltd's latest EBIT is Rs. 48.78 Cr, surpassing the average EBIT of Rs. 68.07 Cr over the 5 years..